Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / SHS
-
Total 13F shares
-
22,519,364
-
Share change
-
-1,159,568
-
Total reported value
-
$134,664,980
-
Price per share
-
$5.98
-
Number of holders
-
45
-
Value change
-
-$9,566,633
-
Number of buys
-
25
-
Number of sells
-
19
Institutional Holders of NABRIVA THERAPEUTICS PLC - SHS as of Q4 2017
As of 31 Dec 2017,
NABRIVA THERAPEUTICS PLC - SHS was held by
45 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
22,519,364 shares.
The largest 10 holders included
Vivo Capital, LLC, ORBIMED ADVISORS LLC, Novo Holdings A/S, venBio Partners L.P., WELLINGTON MANAGEMENT GROUP LLP, BAKER BROS. ADVISORS LP, MILLENNIUM MANAGEMENT LLC, Hillhouse Capital Management, Ltd., Alyeska Investment Group, L.P., and Rock Springs Capital Management LP.
This page lists
45
institutional shareholders reporting positions in this security
for the Q4 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.